Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced a virtual webinar on July 13, 2022, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options. The event will address the current landscape of Hereditary Angioedema (HAE), featuring insights from community members and physicians. Key speakers include Anthony J. Castaldo from HAE International, Dr. Marc A. Riedl from UCSD, Berndt Modig, and Dr. Peng Lu from Pharvaris. Registration for the live webcast is available on their website, with an archived replay accessible for 30 days post-event.

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that it will host a virtual webinar, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options on Wednesday, July 13, 2022, at 10:00 a.m. ET/16:00 CET.

The virtual event will highlight several topics related to today’s HAE landscape, including a community member and physician perspective, as well as current therapeutic needs, followed by a Q&A session. Presenters for the event are:

• Anthony J. Castaldo, co-founder and President, HAE International (HAEi), and President, U.S. Hereditary Angioedema Association (HAEA)
• Marc A. Riedl, M.D., M.S., Professor of Medicine, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center at the University of California San Diego (UCSD), and the Training Program Director for Allergy/Immunology at UCSD
• Berndt Modig, Chief Executive Officer, Pharvaris
• Peng Lu, M.D., Ph.D., Chief Medical Officer, Pharvaris

To register for the live webcast, please visit https://ir.pharvaris.com/news-events/events-presentations in the News and Events section of the company’s website. Following the live webcast, an archived replay will be available for at least 30 days after the event.

About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/

Contact
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com
+1-617-710-7305

FAQ

What is the date of the Pharvaris webinar on HAE?

The Pharvaris webinar titled 'Expert Perspectives on HAE: Unmet Needs and Therapeutic Options' is scheduled for July 13, 2022.

Who are the speakers at the Pharvaris HAE webinar?

Speakers include Anthony J. Castaldo, Dr. Marc A. Riedl, Berndt Modig, and Dr. Peng Lu.

How can I register for the Pharvaris HAE webinar?

You can register for the webinar by visiting the Events section on the Pharvaris website.

Will there be a replay available for the Pharvaris HAE webinar?

Yes, an archived replay of the Pharvaris HAE webinar will be available for at least 30 days after the live event.

What topics will be covered in the Pharvaris HAE webinar?

The webinar will cover various topics related to HAE, including unmet needs and current therapeutic options.